Sermorelin

Mechanism

Evidence tier: 2 — GHRH receptor pharmacology characterized in human dynamic-testing studies; downstream GH/IGF-1 effects measured in adult and pediatric cohorts.

Sermorelin (GRF 1-29 NH₂) is a synthetic 29-amino-acid analog of growth hormone-releasing hormone (GHRH), representing the N-terminal active fragment of endogenous GHRH. It is the shortest peptide that retains full GHRH biological activity. Mechanistically, sermorelin binds the GHRH receptor on anterior pituitary somatotrophs and stimulates physiologic, pulsatile release of endogenous growth hormone (GH). Because the pituitary remains the rate-limiting step, sermorelin produces GH secretion in patterns that approximate native diurnal rhythms — most prominently amplifying the nocturnal GH pulse. Negative feedback via somatostatin and IGF-1 caps the response, which is why overdose-mediated GH excess is mechanistically constrained, as Walker 2006 (PMID 18046908) describes. This contrasts with exogenous recombinant GH (rhGH), which bypasses pituitary regulation entirely and produces non-pulsatile, supraphysiologic serum GH that can suppress endogenous secretion. The physiologic-pulsatility distinction is the central pharmacologic argument for using GHRH analogs over rhGH in age-related GH decline.

Typical protocols

Evidence tier: 5 — Adult community-anti-aging dosing is convention-derived. Pediatric GHD dosing is FDA-labeled (historical Geref formulation).

The historical FDA-approved pediatric indication used sermorelin (Geref) at 0.03 mg/kg subcutaneously at bedtime for idiopathic GH deficiency. The product was discontinued from US commercial supply in 2008, and current sermorelin use is via 503A compounding pharmacies.

Adult anti-aging and age-related GH decline protocols (community/compounded use):

• Dose: 200-500 mcg subcutaneously, typically 300 mcg
• Timing: At bedtime on an empty stomach (the empty-stomach requirement is to avoid postprandial somatostatin suppression of the response)
• Frequency: 5 nights per week (5-on, 2-off) or daily, depending on prescriber preference
• Cycle length: Most protocols run 3-6 months with reassessment of IGF-1 and clinical response; some clinicians use longer continuous schedules
• Monitoring: Baseline + follow-up IGF-1 at 8-12 weeks; clinical endpoints (sleep quality, body composition, recovery)

Some prescribers stack sermorelin with a GHRP (ghrelin mimetic) — typically ipamorelin — to combine GHRH and ghrelin-receptor pathways. See CJC-1295 + Ipamorelin for the most common community variant of this pattern.

Evidence by indication

Evidence tier: 2 — Pediatric idiopathic GH deficiency has Phase 3 / FDA-label evidence; adult anti-aging applications have smaller observational and mechanistic human data, not RCT-grade.

Pediatric idiopathic GH deficiency: Prakash & Goa 1999 (PMID 18031173) summarized the trial program supporting FDA approval. Sermorelin produced clinically meaningful growth velocity increases in confirmed GHD pediatric patients across multiple trials. This is the highest-quality evidence base for the molecule, but represents a discontinued indication in current US practice.

Adult-onset GH insufficiency / age-related GH decline: Walker 2006 (PMID 18046908) is the most-cited review framing sermorelin as a more physiologic alternative to rhGH for adult GH replacement. The evidence base for sermorelin specifically in adult anti-aging is observational and mechanistic rather than RCT-derived. Endpoints in adult studies have included IGF-1 normalization, body composition (DEXA-measured lean mass), sleep architecture, and patient-reported quality of life. Effect sizes are modest compared to rhGH but with a meaningfully better safety profile.

Body composition during caloric restriction: Limited human data. The mechanistic rationale parallels the tesamorelin GLP-1 adjunct hypothesis — GHRH-mediated GH/IGF-1 elevation may support lean-mass preservation — but tesamorelin has substantially more direct evidence in that context.

Sleep and recovery: Endogenous GH is closely tied to slow-wave sleep. Anecdotal and small-cohort reports describe improved deep-sleep architecture with sermorelin; controlled trial data is limited.

Safety profile

Evidence tier: 2 — Pediatric trial pharmacovigilance + adult observational use over two decades; no major safety signals reported.

Sermorelin has a clean documented safety profile relative to rhGH. The most common adverse events are injection-site reactions (erythema, pain, occasional swelling) and transient headache or facial flushing in the first weeks of dosing. Because GH release is rate-limited by pituitary regulation and capped by somatostatin negative feedback, the rhGH-class concerns — supraphysiologic IGF-1, fluid retention, carpal tunnel syndrome, glucose intolerance, theoretical mitogenic concern — are markedly attenuated. Walker 2006 emphasizes that the negative-feedback architecture makes pharmacologic overdose mechanistically difficult.

Contraindications: active or recent malignancy (the IGF-1 elevation is a relative contraindication for several oncologic histologies), known pituitary disease or pituitary surgery without endocrinology workup, severe untreated hypothyroidism, and pregnancy. Patients with diabetic retinopathy should use with endocrinology supervision given the GH-axis stimulation. WADA prohibits sermorelin in-competition and out-of-competition for athletes.

Where it fits relative to alternatives

Evidence tier: 5 — Editorial positioning across the GH-axis molecule landscape.

Within the GH-axis space:

• vs. CJC-1295 + Ipamorelin: Sermorelin is the older, more clinically documented GHRH analog with a shorter half-life (~10-20 minutes). CJC-1295 (DAC variant) has a ~6-8 day half-life that produces tonic rather than pulsatile GH elevation. Sermorelin is the more physiologic choice; CJC-1295/Ipamorelin is the more dose-convenient choice. Patient preference and prescriber convention drive most selection.
• vs. Tesamorelin: Tesamorelin is FDA-approved for HIV-associated visceral adipose tissue with the strongest RCT evidence base of any GHRH analog. Tesamorelin is preferred when visceral fat reduction is the primary indication. Sermorelin is the lower-cost, longer-history option for general age-related GH decline.
• vs. rhGH (somatropin): Sermorelin and the other GHRH analogs preserve pulsatile physiology and the negative-feedback safety architecture; rhGH does not. Sermorelin is the conservative choice for adults considering GH-axis support without diagnosed pituitary deficiency.

Regulatory status + access

Evidence tier: 5 — Regulatory-process content.

Sermorelin is on the FDA bulks list for 503A compounding and remains lawfully available through compounding pharmacy partnerships in 2026. The original commercial product (Geref) was discontinued in 2008, but the molecule is well-established in compounding practice and not currently a target of the 503A enforcement actions affecting BPC-157, TB-500, and other Category 2 molecules. Access is via prescriber + 503A pharmacy partnership, frequently through telehealth — see the clinic directory. WADA-prohibited; athletes should not use it. Discuss any GH-axis intervention with a clinician familiar with endocrine monitoring.

References

• Prakash A, Goa KL. 1999. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. PMID 18031173
• Walker RF. 2006. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. PMID 18046908
• Falutz J, Allas S, Blot K, et al. 2007. Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV. N Engl J Med. PMID 18057338

Limitations

Sermorelin should not be used in patients with active or recent malignancy (IGF-1 elevation is a relative contraindication for several histologies), patients with diabetic retinopathy without endocrinology supervision, pregnant or nursing patients, patients with uncontrolled hypothyroidism, patients with documented pituitary disease or post-pituitary surgery without specialist workup, or anyone subject to WADA testing.

The cited evidence cannot tell us whether long-term adult anti-aging use produces measurable healthspan or lifespan benefit, what the right discontinuation strategy is for chronic users, or whether sermorelin meaningfully outperforms placebo on patient-centered endpoints in adult non-deficient populations. We would change our framing on a registration-quality adult RCT with body-composition or healthspan endpoints, or new pharmacovigilance signal from the 503A compounding cohort.